Skip to main content

Table 1 Outcomes which were reported

From: One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis

Studies

Outcomes reported

Follow up time period

Hemert 2020 [13]

TLF, NACE, all-cause mortality, cardiac death, MI, stent thrombosis, late stent thrombosis, any unplanned revascularization, TLR, stroke, major bleeding

12 months

Romaguera 2022 [14]

TLF, cardiac death, MI, all-cause mortality, any revascularization, TVR, stent thrombosis, late stent thrombosis, acute and sub-acute stent thrombosis, definite, possible and probable stent thrombosis, major adverse cardiac events

12 months

Rozemeijer 2017 [15]

All-cause mortality, TLF, cardiac death, MI, TLR, TVR, any revascularization, stent thrombosis, definite, possible and probable stent thrombosis, early and late stent thrombosis, major adverse cardiac events, major bleeding (BARC ≥ 3)

12 months

Rozemeijer 2018 [16]

Major adverse cardiac events, TLF, all-cause death, cardiac death, MI, definite or probable stent thrombosis, stent thrombosis, stroke, TLR, major bleeding (BARC ≥ 3)

12 months

  1. NACE Net adverse cardiovascular events, TLF target lesion failure, MI Myocardial infarction, TLR Target lesion revascularization, TVR Target vessel revascularization, BARC Bleeding defined by the academic research consortium